Zurcher Kantonalbank Zurich Cantonalbank Acquires 6,320 Shares of Envista Holdings Co. (NYSE:NVST)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Envista Holdings Co. (NYSE:NVST) by 17.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,057 shares of the company’s stock after purchasing an additional 6,320 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Envista were worth $811,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of NVST. Venturi Wealth Management LLC raised its position in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after purchasing an additional 1,638 shares during the period. GAMMA Investing LLC raised its position in shares of Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after purchasing an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Envista in the fourth quarter valued at approximately $53,000. KBC Group NV raised its position in shares of Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after purchasing an additional 3,082 shares during the period. Finally, Glenmede Trust Co. NA bought a new stake in shares of Envista in the third quarter valued at approximately $217,000.

Envista Price Performance

NVST stock opened at $16.63 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a 52 week low of $15.15 and a 52 week high of $23.00. The firm’s fifty day moving average is $19.76 and its 200 day moving average is $19.58. The firm has a market cap of $2.86 billion, a P/E ratio of -2.56, a P/E/G ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Research analysts predict that Envista Holdings Co. will post 1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research note on Saturday, March 8th. Piper Sandler increased their target price on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Jefferies Financial Group increased their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Finally, New Street Research set a $19.00 target price on shares of Envista in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and a consensus price target of $20.18.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.